|
T-Cell LymphomaThere are many types of T-cell lymphoma, just as there are many B-cell types of lymphoma. Although this page appears grouped with the other aggressive forms of NHL there are also indolent T-cell types so if you don't see your type here, look in the indolent lymphoma section.
There is still no consensus about whether T-cell lymphomas respond as well to treatment as their corresponding B-cell types. Most experts will agree that they remain a challenge to treat.
Here are some excellent articles that discuss T-cell lymphomas in-depth.
This first link is to a webcast from Jasmine Zain, MD Columbia University Medical Center, New York.(Approx 45 minutes long)
Next we have The CancerNetworks latest series about T-cell lymphomas. Peripheral T-cell lymphomas: Their time has come
Next we have the Grand Rounds in Hematology newsletter from Bloodline. Click here to read the newsletter
The Cancer network's T-cell lymphoma series. Primary Cutaneous and Systemic Anaplastic Large Cell Lymphoma
From the prestigious journal Blood, this next link is a thorough review of all the peripheral T-cell lymphomas. It discusses their pathology and biology, what the prognosis is for the various types, and current and new treatment strategies. It is a must read for anyone wishing to learn about peripheral T-cell lymphoma. Peripheral T-cell lymphoma from the Journal Blood
Next is a review of the status of using stem cell transplants in the treatment of T-cell lymphoma, from the journal, Annals of Oncology. Stem-cell transplantation in T-cell non-Hodgkin’s lymphomas
Topics covered in the above newsletter include:
Below is an article from the ASH education series that reviews the biology, prognosis and treatment options for T-cell lymphomas, with an emphasis on peripheral T-cell types. ASH education review of T-cell lymphomas
The following article from the Blood Journal explores how the type of skin erruption is a prognostic factor in cutaneous Adult T-cell Lymphoma/Leukaemia Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma
Another important new treatment is Pralatrexate. The recently published PROPEL clinical trial showed a 27% response rate in patients with relapsed or refractory Peripheral T-cell lymphoma. Click the link below to read the press release from Allos Therapeutics.
|